Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion type Assertion NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_head.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion description "[The distribution of the treatment-related MDS cases was different than 'de novo' MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_provenance.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion evidence source_evidence_literature NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_provenance.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion SIO_000772 3504435 NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_provenance.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion wasDerivedFrom befree-20150227 NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_provenance.
- NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_assertion wasGeneratedBy ECO_0000203 NP605959.RAuQFxUIsVvJCdxge7LFBxgfIRqRG-fIG-0I6FODjkdBA130_provenance.